Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Inc., a clinical-stage biotech firm focused on non-hallucinogenic neuroplastogen-derived therapeutics, announced a 1-for-10 reverse share split effective May 21, 2026. This move aims to regain compliance with Nasdaq's Minimum Bid Price Rule. The reverse split will reduce outstanding common shares from approximately 10.2 million t…